Northern Trust Corp Puma Biotechnology, Inc. Transaction History

Northern Trust Corp

$658 Billion
Q1 2025

A detailed history of Northern Trust Corp transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 317,438 shares of PBYI stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

317,438

Previous 325,417 2.45%

Holding current value

$1.07 Million

Previous $992,000 5.34%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$2.76 - $3.88 $22,022 - $30,958	-7,979 Reduced 2.45%	317,438 $939,000
Q4 2024 Feb 14, 2025	BUY	$2.42 - $3.39 $18,580 - $26,028	7,678 Added 2.42%	325,417 $992,000
Q3 2024 Nov 13, 2024	BUY	$2.25 - $4.03 $478,532 - $857,104	212,681 Added 202.44%	317,739 $810,000
Q2 2024 Aug 14, 2024	BUY	$2.92 - $5.83 $62,841 - $125,467	21,521 Added 25.76%	105,058 $342,000
Q1 2024 May 14, 2024	SELL	$4.29 - $7.4 $969 - $1,672	-226 Reduced 0.27%	83,537 $442,000
Q4 2023 Feb 13, 2024	BUY	$2.23 - $4.49 $31,913 - $64,256	14,311 Added 20.61%	83,763 $362,000
Q3 2023 Nov 13, 2023	SELL	$2.63 - $4.09 $376 - $584	-143 Reduced 0.21%	69,452 $182,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $639 - $880	-246 Reduced 0.35%	69,595 $245,000
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $7,525 - $16,412	3,405 Added 5.13%	69,841 $215,000
Q4 2022 Feb 13, 2023	SELL	$2.12 - $5.08 $5,331 - $12,776	-2,515 Reduced 3.65%	66,436 $281,000
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $79 - $134	-35 Reduced 0.05%	68,951 $163,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.3 $352,841 - $709,985	-215,147 Reduced 75.72%	68,986 $197,000
Q1 2022 May 13, 2022	SELL	$2.13 - $3.24 $44,796 - $68,140	-21,031 Reduced 6.89%	284,133 $818,000
Q4 2021 Feb 08, 2022	SELL	$2.85 - $6.58 $127,218 - $293,718	-44,638 Reduced 12.76%	305,164 $927,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $30,438 - $43,109	4,591 Added 1.33%	349,802 $2.45 Million
Q2 2021 Aug 13, 2021	SELL	$8.98 - $11.6 $3,592 - $4,640	-400 Reduced 0.12%	345,211 $3.17 Million
Q1 2021 May 12, 2021	SELL	$9.38 - $13.63 $196,323 - $285,275	-20,930 Reduced 5.71%	345,611 $3.36 Million
Q4 2020 Feb 11, 2021	SELL	$7.78 - $12.13 $46,143 - $71,943	-5,931 Reduced 1.59%	366,541 $3.76 Million
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $204,573 - $239,888	-21,534 Reduced 5.47%	372,472 $3.76 Million
Q2 2020 Aug 14, 2020	BUY	$7.01 - $13.24 $98,055 - $185,201	13,988 Added 3.68%	394,006 $4.11 Million
Q1 2020 May 14, 2020	BUY	$6.28 - $14.57 $41,303 - $95,826	6,577 Added 1.76%	380,018 $3.21 Million
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $91,468 - $150,992	-14,072 Reduced 3.63%	373,441 $3.27 Million
Q3 2019 Nov 13, 2019	BUY	$8.75 - $12.85 $272,623 - $400,367	31,157 Added 8.74%	387,513 $4.17 Million
Q2 2019 Aug 13, 2019	BUY	$12.3 - $35.76 $18,167 - $52,817	1,477 Added 0.42%	356,356 $4.53 Million
Q1 2019 May 13, 2019	BUY	$20.77 - $42.37 $41,415 - $84,485	1,994 Added 0.57%	354,879 $13.8 Million
Q4 2018 Feb 12, 2019	SELL	$20.07 - $46.7 $62,658 - $145,797	-3,122 Reduced 0.88%	352,885 $7.18 Million
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $323,708 - $470,241	7,857 Added 2.26%	356,007 $16.3 Million
Q2 2018 Sep 18, 2018	SELL	$48.3 - $68.25 $113,311 - $160,114	-2,346 Reduced 0.67%	348,150 $20.6 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $429,000 - $606,196	8,882 Added 2.6%	350,496 $20.7 Million
Q1 2018 May 09, 2018	BUY	$59.7 - $99.25 $291,753 - $485,034	4,887 Added 1.45%	341,614 $23.2 Million
Q4 2017 Feb 14, 2018	SELL	$93.85 - $132.45 $857,132 - $1.21 Million	-9,133 Reduced 2.64%	336,727 $33.3 Million
Q3 2017 Nov 13, 2017	BUY	$72.0 - $119.75 $24.9 Million - $41.4 Million	345,860	345,860 $41.4 Million

Others Institutions Holding PBYI

# of Institutions

116

Shares Held

30.9M

Call Options Held

32.7K

Put Options Held

200

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $154M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Puma Biotechnology, Inc. Transaction History